InMed Pharmaceuticals Inc. (INM) Reports Q2 Loss of $0.37
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results
February 11, 2021 7:30 AM ESTVANCOUVER, BC, Feb. 11, 2021 /PRNewswire/ -Â InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM)Â (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the second quarter of fiscal year 2021 ("2Q21") which ended December 31, 2020.
Conference Call & Webcast1:
Thursday,... More
